16- (4- fluorophenoxy)- 3- oxa- 5,6,15- trihydroxy- 7,9,13- hexadecatrien- 11- ynoic acid

Subscribe to Selected New Research on 16-(4-fluorophenoxy)-3-oxa-5,6,15-trihydroxy-7,9,13-hexadecatrien-11-ynoic acid

1 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: an NSAID; ZK-192 is the sodium salt. structure in first source

Also Known As:

16-FOTH3A; ZK-192

Bio-Agent Context: Research Results

Lipids: 13315

Fatty Acids: 4660

Unsaturated Fatty Acids: 2221

Eicosanoids: 1153

Lipoxins: 160

16-(4-fluorophenoxy)-3-oxa-5,6,15-trihydroxy-7,9,13-hexadecatrien-11-ynoic acid: 1

Related Diseases

1.	Weight Loss (Weight Reduction) 11/02/2004 - "ZK-192 attenuated weight loss, macroscopic and histologic colon injury, mucosal neutrophil infiltration, and colon wall thickening" Get all the results and reference details, order at left...
2.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/02/2004 - "The combined antiinflammatory and immunomodulatory effects of ZK-192 in TNBS colitis suggest that ATL analogs may be an attractive oral treatment approach for inflammatory bowel diseases." Get all the results and reference details, order at left...
3.	Colitis 11/02/2004 - "When dosed orally once daily, 300 and 1,000 mug/kg ZK-192 markedly attenuated TNBS colitis in rodents both in preventive and therapeutic regimens" 11/02/2004 - "Oral efficacy and mechanism of action of ZK-192, a beta-oxidation-resistant 3-oxa-ATL analog, were examined in trinitrobenzenesulphonate (TNBS)-induced colitis" 11/02/2004 - "The combined antiinflammatory and immunomodulatory effects of ZK-192 in TNBS colitis suggest that ATL analogs may be an attractive oral treatment approach for inflammatory bowel diseases." 11/02/2004 - "ZK-192 also prevented colitis in lymphocyte-deficient severe combined immunodeficient mice, with approximately 75% inhibition of mucosal tumor necrosis factor alpha and IL-2 levels" Get all the results and reference details, order at left...
3 Diseases and 1 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Interleukin-2 (IL2)
2 Drugs and Important Bio-Agents and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>